Bristol-Myers Squibb Stock On Fire: Up 7.6% With 5-Day Winning Streak
Bristol-Myers Squibb (BMY) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 7.6% return. The company has gained about $7.0 Bil in value over the last 5 days, with its current market capitalization at about $100 Bil. The stock remains 8.6% below its value at the end of 2024. This compares with year-to-date returns of 15.8% for the S&P 500.
Bristol-Myers Squibb’s recent streak was fueled by the European Commission’s approval for CAR T cell therapy Breyanzi in mantle cell lymphoma, expanding its market reach. Investor optimism also surged from positive read-across for its cardiovascular pipeline, driven by a rival’s strong trial data.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is a near-equal mix of good and bad in BMY stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (see Buy or Sell BMY).
For quick background, BMY provides biopharmaceutical products worldwide, specializing in hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 treatments, including Revlimid for multiple myeloma.
- Market Leader Bristol-Myers Squibb Stock at 21% Discount, Worth Buying?
- BMY Stock Down -6.3% after 8-Day Loss Streak
- Is Bristol Myers Squibb Undervalued?
- BMY Stock Down -12% after 6-Day Loss Streak
- Is It Time To Buy Bristol Myers Squibb Stock?
- How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Comparing BMY Stock Returns With The S&P 500
The following table summarizes the return for BMY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | BMY | S&P 500 |
|---|---|---|
| 1D | 0.4% | 0.7% |
| 5D (Current Streak) | 7.6% | 2.6% |
| 1M (21D) | 15.0% | -1.1% |
| 3M (63D) | 6.5% | 4.8% |
| YTD 2025 | -8.6% | 15.8% |
| 2024 | 15.8% | 23.3% |
| 2023 | -26.1% | 24.2% |
| 2022 | 19.0% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 136 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 20 | 7 |
| 4D | 94 | 0 |
| 5D | 14 | 0 |
| 6D | 3 | 0 |
| 7D or more | 5 | 1 |
| Total >=3 D | 136 | 8 |
Key Financials for Bristol-Myers Squibb (BMY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $45.0 Bil | $48.3 Bil |
| Operating Income | $8.2 Bil | $5.9 Bil |
| Net Income | $8.0 Bil | $-8.9 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $12.3 Bil | $12.2 Bil |
| Operating Income | $3.8 Bil | $3.6 Bil |
| Net Income | $1.3 Bil | $2.2 Bil |
While BMY stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.